ABSTRACT OF THE DISCLOSURE

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:



A is O, S, or NR^4; B is a bond or CR^5R^6;

R^4, to R^6 are H, C_1 to C_6 alkyl, C_2 to C_6 alkenyl, C_2 to C_6 alkynyl, C_3 to C_8 cycloalkyl, aryl, or heterocyclic, or R^4 and R^5 are fused to form a ring; R^1 is H, OH, NH_2, C_1 to C_6 alkyl, C_3 to C_6 alkenyl, alkynyl, or COR^A; R^A is as defined; R^2 is H, halogen, CN, NO_2, C_1 to C_6 alkyl, C_1 to C_6 alkoxy, or C_1 to C_6 aminoalkyl; R^3 is a substituted benzene ring, or heteroaromatic ring, in combination with a progestational agent and/or an estrogen to treat or prevent secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas and adenocarcinomas, and contraception, among others.